Leukoderma


Also found in: Dictionary, Thesaurus, Medical, Wikipedia.
Related to Leukoderma: vitiligo

leukoderma

[‚lü·kə′dər·mə]
(medicine)
Defective skin pigmentation, especially the congenital absence of pigment in patches or bands.

Leukoderma

 

a disorder of the pigmentation of the skin manifested by a decrease in or complete loss of pigment.

Leukoderma can develop from previous skin lesions (seborrheic eczema, psoriasis, parapsoriasis, lichen ruber, pityriasis versicolor) or from certain medications (Chrysorabin, Psoriasin, pyrogallol), or as a symptom of a systemic disease (for example, secondary syphilis). It is characterized by the appearance on the skin of round depigmented spots of various size surrounded by hyperpigmentation. Syphilitic leukoderma develops three to six months after infection with syphilis and concentrates mainly on the posterolateral surface of the neck (less commonly, on the back, abdomen, and lateral surface of the chest). Leukoderma patients have no subjective sensations associated with the disease. Treatment is directed at the primary condition.

REFERENCES

Mnogotomnoe rukovodstvo po dermato-venerologii, vols. 1–3. Moscow, 1959–64.
Mashkilleison, L. N. Chastnaia dermatologiia. Moscow, 1965.

I. IA. SHAKHTMEISTER

Mentioned in ?
References in periodicals archive ?
Scientists have found that application of a poly-herbal ointment with chickpeas as its base can effectively treat Leukoderma.
When contact leukoderma from a potent depigmenting chemical is suspected, patch tests done to determine the allergen should be done, Dr.
Brian Biesman, Director of the Nashville Center for Laser and Facial Surgery in Nashville, Tennessee is leading the development of the Excilite for treatment of leukoderma arising as a result of previous laser or chemical treatments.
PhotoMedex is engaged in the development of proprietary excimer laser and fiber optic systems and techniques directed toward dermatological applications, with FDA approval to market the XTRAC(R) laser system for the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma.
PhotoMedex is engaged in the development of proprietary excimer laser and fiber optic systems and techniques directed toward dermatological applications, with FDA 510(k) clearances to market the XTRAC(R) laser system for the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma.
PhotoMedex develops proprietary excimer laser and fiber optic systems and techniques directed toward dermatological applications, with FDA 510(k) clearances to market the XTRAC[R] laser system for the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma.
PhotoMedex is engaged in the development of proprietary excimer laser and fiber optic systems and techniques directed toward dermatological applications, with FDA 510(k) clearances to market the XTRAC([R]) laser system for the treatment of psoriasis, vitiligo, atopic dermatitis and leukoderma.
Food and Drug Administration 510k clearance to market the new, more powerful and faster XTRAC Velocity[TM] excimer laser system to treat psoriasis, vitiligo, atopic dermatitis and leukoderma.
Food and Drug Administration 510k clearance to market the new, more powerful, faster XTRAC[R] Velocity[TM] excimer laser system to treat psoriasis, vitiligo, atopic dermatitis and leukoderma.